FCVAX
Price
$24.74
Change
+$0.03 (+0.12%)
Updated
Aug 13 closing price
Net Assets
5.47B
VSCAX
Price
$32.72
Change
-$0.18 (-0.55%)
Updated
Aug 13 closing price
Net Assets
11.79B
Interact to see
Advertisement

FCVAX vs VSCAX

FCVAX vs VSCAX Comparison Chart in %
View a ticker or compare two or three
VS
FCVAX vs. VSCAX commentary
Aug 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FCVAX is a StrongBuy and VSCAX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCAX has more cash in the bank: 11.8B vs. FCVAX (5.47B). FCVAX pays higher dividends than VSCAX: FCVAX (0.66) vs VSCAX (0.21). FCVAX was incepted earlier than VSCAX: FCVAX (22 years) vs VSCAX (27 years). FCVAX (1.20) is less costly to investors than VSCAX (1.10). FCVAX is a more actively managed with annual turnover of: 96.00 vs. VSCAX (79.00). FCVAX (6%) and VSCAX (6%) have equivalent initial investment costs. FCVAX has a lower initial minimum investment than VSCAX: FCVAX (0) vs VSCAX (1000). VSCAX annual gain was more profitable for investors over the last year : 32.09 vs. FCVAX (21.42). VSCAX return over 5 years is better than : 64.09 vs. FCVAX (18.60).
FCVAXVSCAXFCVAX / VSCAX
Total Expense Ratio1.201.10109%
Annual Report Gross Expense Ratio1.201.10109%
Fund Existence22 years27 years-
Gain YTD28.69829.98896%
Front Load6%6%105%
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets5.47B11.8B46%
Annual Yield % from dividends0.660.21317%
Returns for 1 year21.4232.0967%
Returns for 3 years32.5669.6747%
Returns for 5 years18.6064.0929%
Returns for 10 years42.13100.3142%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYDVX2.710.03
+1.12%
Royce Smid-Cap Total Return Service
SUHCX23.53N/A
N/A
DWS Health and Wellness C
MGTIX44.36N/A
N/A
MFS Massachusetts Inv Gr Stk I
FSCRX27.67N/A
N/A
Fidelity Small Cap Discovery
BIVRX17.53N/A
N/A
Invenomic Investor